These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 38156928)

  • 21. Remodeling of the tumor microenvironment via disrupting Blimp1
    Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
    Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunomodulation of HDAC Inhibitor Entinostat Potentiates the Anticancer Effects of Radiation and PD-1 Blockade in the Murine Lewis Lung Carcinoma Model.
    Kim Y; Park K; Kim YJ; Shin SW; Kim YJ; Choi C; Noh JM
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
    Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
    Front Immunol; 2022; 13():794684. PubMed ID: 35720386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
    J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
    Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
    Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner.
    He H; Shi L; Meng D; Zhou H; Ma J; Wu Y; Wu Y; Gu Y; Xie W; Zhang J; Zhu Y
    Cancer Treat Res Commun; 2021; 28():100379. PubMed ID: 33951555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8
    Liu Y; Zhang T; Zhang L; Zhao C; Zhang Z; Wang Z; Gu M; Li W; Li B
    Immunotherapy; 2022 Jun; 14(9):695-708. PubMed ID: 35574588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy.
    Maines LW; Keller SN; Smith CD
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.
    Kato Y; Tabata K; Kimura T; Yachie-Kinoshita A; Ozawa Y; Yamada K; Ito J; Tachino S; Hori Y; Matsuki M; Matsuoka Y; Ghosh S; Kitano H; Nomoto K; Matsui J; Funahashi Y
    PLoS One; 2019; 14(2):e0212513. PubMed ID: 30811474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
    Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation.
    Caudana P; Núñez NG; De La Rochere P; Pinto A; Denizeau J; Alonso R; Niborski LL; Lantz O; Sedlik C; Piaggio E
    Cancer Immunol Res; 2019 Mar; 7(3):443-457. PubMed ID: 30651291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engineered Hybrid Treg-Targeted Nanosomes Restrain Lung Immunosuppression by Inducing Intratumoral CD8
    Domvri K; Petanidis S; Zarogoulidis P; Anestakis D; Charalampidis C; Tsavlis D; Huang H; Freitag L; Hohenforst-Schmidt W; Matthaios D; Katopodi T; Porpodis K
    Int J Nanomedicine; 2022; 17():4449-4468. PubMed ID: 36172007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer.
    Yi M; Wu Y; Niu M; Zhu S; Zhang J; Yan Y; Zhou P; Dai Z; Wu K
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncolytic adenovirus H101 ameliorate the efficacy of anti-PD-1 monotherapy in colorectal cancer.
    Huang L; Zhao H; Shan M; Chen H; Xu B; He Y; Zhao Y; Liu Z; Chen J; Xu Q
    Cancer Med; 2022 Dec; 11(23):4575-4587. PubMed ID: 35762456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function.
    Kim HR; Park HJ; Son J; Lee JG; Chung KY; Cho NH; Shim HS; Park S; Kim G; In Yoon H; Kim HG; Jung YW; Cho BC; Park SY; Rha SY; Ha SJ
    J Immunother Cancer; 2019 Dec; 7(1):339. PubMed ID: 31801611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
    Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
    FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
    Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
    Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer.
    Kasikara C; Davra V; Calianese D; Geng K; Spires TE; Quigley M; Wichroski M; Sriram G; Suarez-Lopez L; Yaffe MB; Kotenko SV; De Lorenzo MS; Birge RB
    Cancer Res; 2019 May; 79(10):2669-2683. PubMed ID: 30877108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.